治疗2型糖尿病：肠促胰岛素类似物和增强剂。
Treating type 2 diabetes: incretin mimetics and enhancers.
作者信息
Janosz Katherine E Nori, Zalesin Kerstyn C, Miller Wendy M, McCullough Peter A
机构信息
William Beaumont Hospital, Royal Oak, Michigan, USA.
出版信息
Ther Adv Cardiovasc Dis. 2009 Oct;3(5):387-95. doi: 10.1177/1753944709341377.
As a consequence of excess abdominal adiposity and genetic predisposition, type 2 diabetes is a progressive disease, often diagnosed after metabolic dysfunction has taken hold of multiple organ systems. Insulin deficiency, insulin resistance and impaired glucose homeostasis resulting from beta-cell dysfunction characterize the disease. Current treatment goals are often unmet due to insufficient treatment modalities. Even when combined, these treatment modalities are frequently limited by safety, tolerability, weight gain, edema and gastrointestinal intolerance. Recently, new therapeutic classes have become available for treatment. This review will examine the new therapeutic classes of incretin mimetics and enhancers in the treatment of type 2 diabetes.
由于腹部脂肪过多和遗传易感性，2型糖尿病是一种进行性疾病，通常在代谢功能障碍影响多个器官系统后才被诊断出来。胰岛素缺乏、胰岛素抵抗以及由β细胞功能障碍导致的葡萄糖稳态受损是该疾病的特征。由于治疗方式不足，目前的治疗目标常常无法实现。即使联合使用，这些治疗方式也常常受到安全性、耐受性、体重增加、水肿和胃肠道不耐受的限制。最近，出现了新的治疗类别用于治疗。本综述将探讨肠促胰岛素类似物和增强剂这些新的治疗类别在2型糖尿病治疗中的应用。
Zotero 插件